ACCESS A Master Digital Surveillance Protocol for COVID-19
Sponsored by Medable
ACCESS enables individuals to contribute to critical research, via an iOS and Android smartphone mobile application. ACCESS combines patient reported outcomes, data from wearable devices and real-world data (such as claims, EHRs, etc), with an opt-in to participate in current and future studies for diagnostics, treatments and vaccines.
The data that people share can be quickly and anonymously matched to research studies, providing researchers with a foundational framework for dynamic research at scale and participants a way to be personally matched and prescreened for future research.
About COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
How is this study designed?
Study type: Observational Estimated Enrollment: 1000000 participants Actual Study Start Date: April 20, 2020 Estimated Study Completion Date: October 1, 2031
Who is this study for?
Inclusion Criteria:
- Aged 18 years or older
- Able to provide electronic informed consent
- US Resident
- Read and comprehend English
Exclusion Criteria:
- Do not have a personal smartphone
What should I expect?
ACCESS (American COVID-19 Collaborative Enabling Seamless Science), a novel COVID-19 digital research infrastructure, provides a mobile app tool for participants to report specific data and facilitate remote access to accelerate critical research and clinical treatment development.
Have a question?
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.